[Articles] Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

19:55 EST 5 Mar 2014 | The Lancet

Increased clinical disease activity associated with atacicept suggests that the role of B cells and humoral immunity in multiple sclerosis is complex. For studies that explore therapeutic immunomodulation in multiple sclerosis, rigorous monitoring fo...

Original Article: [Articles] Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

NEXT ARTICLE

More From BioPortfolio on "[Articles] Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial"

Search BioPortfolio:
Advertisement

Relevant Topic

Immunology
Latest News Clinical Trials Research Drugs Reports Corporate
Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand and prevent autoimmune condtions, cancers of immune cells and immune deficiencies. Immunotherapy i...

Advertisement

Searches Linking to this Story